IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Attorney Docket No. 42534-708.313
`PATENT
`
`Inventor(s): TALASAZet al.
`
`Serial Number: 17/809,544
`
`Filing Date: June 28, 2022
`
`Title: METHODS AND SYSTEMS FOR
`
`DETECTING GENETIC VARIANTS
`
`
`Confirmation No.: 9046
`
`Customer No.: 115823
`
`Group Art Unit: 1637
`
`Examiner: Kenneth R. HORLICK
`
`FILED ELECTRONICALLY ON: October 25, 2022
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria VA 22313-1450
`
`INFORMATION DISCLOSURE STATEMENT
`UNDER37 CFR § 1.97
`
`Commissionerfor Patents:
`
`An Information Disclosure Statement along with attached PTO/SB/08 is hereby submitted. A copy
`
`of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.
`
`The Examiner is requested to review the information provided and to make the information of
`
`record in the above-identified application. The Examiner is further requested to initial and return the
`
`attached PTO/SB/08 in accordance with MPEP § 609.
`
`The right to establish the patentability of the claimed invention over any of the information
`
`provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this
`
`information may not be enabling for the teachings purportedly offered, is hereby reserved.
`
`This statementis not intended to represent that a search has been madeorthat the information cited
`
`in the statementis, or is considered to be, prior art or material to patentability as defined in § 1.56.
`
`Attorney Docket No. 42534-708.313
`
`
`
`A. [] 37 CFR § 1.97 (b). This Information Disclosure Statement should be considered by the Office
`because:
`
`LJ
`
`(1)
`
`It is being filed within 3 months ofthe filing date of a national application and is
`other than a continued prosecution application under § 1.53 (d);
`
`-- OR --
`
`LJ
`
`(2)
`
`It is being filed within 3 monthsof entry ofthe nationalstage as set forth in § 1.491
`in an international application;
`
`--OR --
`
`CJ
`
`(3)
`
`It is being filed before the mailing of a first Office action on the merits;
`
`--OR --
`
`CJ
`
`(4)
`
`It is being filed before the mailing ofa first Office actionafter the filing ofa request
`for continued examination under § 1.114.
`B. XX] 37 CFR § 1.97(c). Althoughthis Information Disclosure Statementis being filed after the period
`specified in 37 CFR § 1.97(b), above, it is filed before the mailing date ofthe earlier of (1) a final office
`action under § 1.113, (2) a notice of allowance under § 1.311, or (3) an action that otherwise closes
`prosecution in the application, this Information Disclosure Statement should be considered becauseit
`is accompanied by oneof:
`LC]
`a statementas specified in §1.97 (e) provided concurrently herewith;
`
`--OR --
`
`xX
`
`a fee of $260.00 as set forth in § 1.17 (p) authorized below, enclosed, or included with the
`paymentof other papersfiled together with this statement.
`C. [J 37 CFR § 1.97 (d). Althoughthis Information Disclosure Statementis beingfiled after the mailing
`date of the earlier of (1) a final office action under § 1.113, (2) a notice of allowance under § 1.311, or
`(3) an action that otherwise closes prosecution in the application,it is being filed before paymentof the
`issue fee and should be considered becauseit is accompanied by:
`
`1. astatement as specified in § 1.97 (e);
`
`-- AND --
`
`il. afee of $260.00 as set forth in §1.17(p) is authorized below,enclosed, or included with
`the paymentof other papers filed together with this Statement.
`D. L] 37 CFR $1.97 (e). Statement.
`
`CJ
`
`LJ
`
`CJ
`
`A statement is provided herewith to satisfy the requirement under 37 CFR §§ 1.97 (c);
`
`-- AND/OR--
`
`A statementis provided herewith to satisfy the requirement under 37 CFR §§ 1.97 (d);
`
`-- AND/OR--
`
`A copy of a dated communication from a foreign patent office clearly showing that the
`information disclosure statement is being submitted within 3 monthsofthe filing date on
`the communication is provided in lieu of a statement under 37 C.F.R. § 1.97(e) (1) as
`provided for under MPEP 609.04(b) V.
`
`Attorney Docket No. 42534-708.313
`
`-2-
`
`
`
`E. [] Statement Under 37 C.F-R. §1.704(d). Each item of information contained in the information
`disclosure statement wasfirst cited in any communication from a patent office in a counterpart foreign
`or international application or from the Office or is a communication that wasissued by a patent office
`in a counterpart foreign or international application or by the Office that was received by an individual
`designated in § 1.56(c) not more than thirty (30) days priorto the filing of this information disclosure
`statement. This statement is made pursuant to the requirements of 37 C.F.R.
`§1.704(d) to avoid
`reduction of the period of adjustment of the patent term for Applicant(s) delay.
`XX] 37 CFR $1.98 (a) (2). The content of the Information Disclosure Statementis as follows:
`L
`
`Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed
`herewith.
`
`F.
`
`-- OR --
`
`xX
`
`Copies of U.S. Patent Documents (issued patents and patent publications) listed on the
`attached Form PTO/SB/08 are not enclosed.
`
`-- AND/OR--
`
`Copies of Foreign Patent Documents and/or Non Patent Literature Documentslisted on the
`attached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2).
`
`-- AND/OR--
`
`L
`
`Copies of pending unpublished U.S. patent applications are enclosed in accordance with
`37 CFR §1.98 (a) (2) (iii).
`G. L] 37 CFR §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or
`references.
`
`L
`
`Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent,
`publication or other information providedthatis not in English is provided herewith.
`CJ
`Pursuant to MPEP 609(B), an English language copy of a foreign search report is
`submitted herewith to satisfy the requirement for a concise explanation where non-
`English language informationis cited in the search report.
`
`-- OR --
`
`LJ
`
`A concise explanation of the relevance of each patent, publication or other
`information provided that is not in English is as follows:
`
`L
`
`Pursuant to 37 CFR §1.98(a) (3) (ii), a copy of a translation, or a portion thereof, of the
`non-English language reference(s) is provided herewith.
`H. [] 37 CFR §1.98(d). Copies of patents, publications and pending U.S. patent applications, or other
`information specified in 37 C.F.R. § 1.98(a) are not provided herewith because:
`L
`
`the information was previously submitted in an
`to 37 CFR $1.98(d)(1)
`Pursuant
`Information Disclosure Statement, or cited by examiner for another application under
`which this application claims priority for an earlier effective filing date under 35 U.S.C.
`120.
`
`Application in which the information was submitted:
`
`Information Disclosure Statement(s) filed on:
`
`AND
`
`Attorney Docket No. 42534-708.313
`
`-3-
`
`
`
`CJ
`
`The information disclosure statement submitted in the earlier application complied with
`paragraphs(a) through (c) of 37 CFR $1.98.
`I. | Fee Authorization. The Commissioneris hereby authorized to charge the above-referenced fees of
`$260.00 and charge any additional fees or credit any overpaymentassociated with this communication
`
`to Deposit Account No. 602231 (Docket No. GH0004-CON 12).
`
`Respectfully submitted,
`
`GUARDANT HEALTH,INC.
`
`
`
` Date: October 25, 2022
`
`By:
`
`/Timothy A. Hott/
`
`Timothy A. Hott
`Registration No.: 67740
`
`GUARDANTHEALTH,INC.
`3100 Hanover St
`Palo Alto, CA 94304
`Customer No. 115823
`
`Attorney Docket No. 42534-708.313
`
`-4-
`
`
